Development of a GC-MS Assay for the Determination of Fentanyl Pharmacokinetics in Rabbit Plasma after Sublingual Spray Delivery

Malkawi, Ahmad H.; Al-Ghananeem, Abeer M.; Crooks, Peter A.

doi:10.1208/s12248-008-9031-x

Cited by 30 publications

(25 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rabbits fasted for 24 h before the experiment and were divided into two groups, each having six animals. The selection of rabbits as animal model for the present study was based on previously published pharmacokinetic studies (31)(32)(33). The first group received orally the 10-mg reference tablets (Zyprexa® by Eli Lilly) and the second group received orally 10-mg CR test tablets of olanzapine.…”

Section: In Vivo Evaluationmentioning

confidence: 99%

Controlled Release Matrix Tablets of Olanzapine: Influence of Polymers on the In Vitro Release and Bioavailability

2010

View full text Add to dashboard Cite

Abstract. Controlled-release (CR) tablet formulation of olanzapine was developed using a binary mixture of Methocel® K100 LV-CR and Ethocel® standard 7FP premium by the dry granulation slugging method. Drug release kinetics of CR tablet formulations F1, F2, and F3, each one suitably compressed for 9-, 12-, and 15-kg hardness, were determined in a dissolution media of 0.1 N HCl (pH 1.5) and phosphate buffer (pH 6.8) using type II dissolution apparatus with paddles run at 50 rpm. Ethocel® was found to be distinctly controlling drug release, whereas the hardness of tablets and pH of the dissolution media did not significantly affect release kinetics. The CR test tablets containing 30% Methocel® and 60% Ethocel® (F3) with 12-kg hardness exhibited pH-independent zero-order release kinetics for 24 h. In vivo performance of the CR test tablet and conventional reference tablet were determined in rabbit serum using high-performance liquid chromatography coupled with electrochemical detector. Bioavailability parameters including C max , T max , and AUC 0-48 h of both tablets were compared. The CR test tablets produced optimized C max and extended T max (P<0.05). A good correlation of drug absorption in vivo and drug release in vitro (R 2 =0.9082) was observed. Relative bioavailability of the test tablet was calculated as 94%. The manufacturing process employed was reproducible and the CR test tablets were stable for 6 months at 40±2°C/75±5% relative humidity. It was concluded that the CR test tablet formulation successfully developed may improve tolerability and patient adherence by reducing adverse effects.

show abstract

Section: In Vivo Evaluationmentioning

confidence: 99%

Controlled Release Matrix Tablets of Olanzapine: Influence of Polymers on the In Vitro Release and Bioavailability

2010

View full text Add to dashboard Cite

show abstract

“…Methods using HPLC-UV, [12][13][14][15] GC-MS, 16) and LC-MS, [17][18][19][20][21][22] have been used to determine the fentanyl concentration in plasma [18][19][20]22) and breast milk. 21) Liquid chromatographytandem mass spectrometry (LC-MS/MS) provides a rapid, sensitive, and specific analysis.…”

mentioning

confidence: 99%

A Simple Liquid Chromatography–Tandem Mass Spectrometry Method for Determination of Plasma Fentanyl Concentration in Rats and Patients with Cancer Pain

Hisada

Katoh

Hitoshi

et al. 2013

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

A fentanyl patch is widely used for the treatment of cancer pain. Its few adverse effects include constipation and drowsiness. The absorption volume of transdermally applied fentanyl may differ according to its site of application and variability in patch adhesion. Since fentanyl is predominantly metabolized by the drug-metabolizing enzyme cytochrome P450 (CYP) 3A4 in the liver, its concentration may vary in cases of physiologically reduced CYP3A4 activity in the liver (liver disease and aging) or on co-administration of drugs. The clinical significance of measuring plasma concentration of fentanyl is high, but conventional methods require complicated processes such as solid-phase extraction and liquid-liquid extraction before the sample is injected into an HPLC system. In this study, a simple liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for determining plasma fentanyl concentrations by deproteinization with acetonitrile. A recovery test was conducted using an absolute calibration curve to confirm the method's linearity and inter-and intra-day reproducibility. The required plasma volume for detection was reduced from 1 mL in the conventional method to 20 µL in the present study, and a good calibration curve was obtained in the concentration range from 0.05 to 5 ng/mL. These findings suggest that the method for sample preparation and quantification developed in this study are appropriate for measuring fentanyl concentration in human plasma in clinical settings.

show abstract

“…Rabbits fasted for 24 h before trial and were divided into two groups, each one having six animals. Selection of rabbits as the animal model for the present study was based on some successfully conducted previously published pharmacokinetic studies (22,29,30). The first group received 4-mg reference conventional tablets and the second group received 4 mg controlled-release (CR) test tablets of risperidone.…”

Section: In Vivo Evaluationsmentioning

confidence: 99%

Development of Controlled-Release Matrix Tablet of Risperidone: Influence of Methocel®- and Ethocel®-Based Novel Polymeric Blend on In Vitro Drug Release and Bioavailability

et al. 2011

View full text Add to dashboard Cite

Abstract. Controlled-release (CR) matrix tablet of 4 mg risperidone was developed using flow bound dry granulation-slugging method to improve its safety profile and compliance. Model formulations F1, F2, and F3, consisting of distinct blends of Methocel® K100 LV-CR and Ethocel® standard 7FP premium, were slugged. Each batch of granules (250-1,000 μm), obtained by crushing the slugs, was divided into three portions after lubrication and then compressed to 9-, 12-, and 15-kg hard tablets. In vitro drug release studies were carried out in 0.1 N HCl (pH 1.2) and phosphate buffer (pH 6.8) using a paddle dissolution apparatus run at 50 rpm. The CR test tablet, containing 30% Methocel® and 60% Ethocel® (F3) with 12-kg hardness, exhibited pH-independent zero-order release kinetics for 24 h. The drug release rate was inversely proportional to the content of Ethocel®, while the gel layer formed of Methocel® helped in maintaining the integrity of the matrix. Changes in the hardness of tablet did not affect the release kinetics. The tablets were reproducible and stable for 6 months at 40±2°C/75±5% relative humidity. Risperidone and its active metabolite, 9-hydroxyrisperidone, present in the pooled rabbit's serum, were analyzed with HPLC-UV at λ max 280 nm. The CR test tablet exhibited bioequivalence to reference conventional tablet in addition to the significantly (p<0.05) optimized peak concentration, C max , and extended peak time, T max , of the active moiety. There was a good association between drug absorption in vivo and drug release in vitro (R 2 =0.7293). The successfully developed CR test tablet may be used for better therapeutic outcomes of risperidone.

show abstract

Development of a GC-MS Assay for the Determination of Fentanyl Pharmacokinetics in Rabbit Plasma after Sublingual Spray Delivery

Cited by 30 publications

References 24 publications

Controlled Release Matrix Tablets of Olanzapine: Influence of Polymers on the In Vitro Release and Bioavailability

Controlled Release Matrix Tablets of Olanzapine: Influence of Polymers on the In Vitro Release and Bioavailability

A Simple Liquid Chromatography–Tandem Mass Spectrometry Method for Determination of Plasma Fentanyl Concentration in Rats and Patients with Cancer Pain

Development of Controlled-Release Matrix Tablet of Risperidone: Influence of Methocel®- and Ethocel®-Based Novel Polymeric Blend on In Vitro Drug Release and Bioavailability

Contact Info

Product

Resources

About